Innovative advancements in blood testing technology are poised to transform patient care,thanks to a significant funding boost from the National Institutes of Health (NIH). rHEALTH, a pioneer in healthcare innovation, has secured $5 million in grants to fast-track the development and FDA approval of its state-of-the-art coagulation tests. These breakthroughs promise to revolutionize the diagnosis and management of critical conditions like hemophilia and blood clotting disorders.
BEDFORD, Mass., Jan. 14, 2025 — rHEALTH announced today that its affiliate, the DNA Medicine Institute (DMI), has been awarded two grants totaling $5 million from the NIH’s National Heart, Lung, and Blood Institute (NHLBI). These funds will support the commercialization of two groundbreaking blood tests: one for hemophilia A and another for monitoring anti-factor Xa activity in patients on oral anticoagulants like Eliquis® and Xarelto®.
The first grant, a $3 million NHLBI Phase IIB Bridge Award, is focused on advancing rHEALTH’s fingerstick-based point-of-care technology. This innovation measures FVIII and emicizumab levels, which are critical for managing hemophilia A—a genetic disorder affecting 1 in 5,000 male births. The second grant, a $2 million Direct to Phase II SBIR award, will fund the development of a rapid test to assess anti-factor Xa activity, addressing a pressing need for patients on blood-thinning medications.
Patients with hemophilia A require lifelong treatment to maintain therapeutic levels of FVIII or emicizumab. Accurate monitoring is essential to prevent complications such as acute bleeding or surgical risks.However, current testing methods are often limited to specialized central laboratories, leaving many patients, notably in underserved regions, underdiagnosed. similarly, over 16 million patients worldwide rely on factor Xa inhibitors, with more than 500,000 experiencing severe bleeding or strokes annually.Timely results are crucial for administering life-saving interventions,and rHEALTH’s tests deliver accurate data in minutes.
“Our mission is to democratize access to critical diagnostic tools,” said Dr. Eugene Chan, CEO of rHEALTH. “Traditionally, tests for hemophilia A and anti-Xa inhibitors are confined to central labs. With rHEALTH’s technology, these tests can now be performed by patients and caregivers, empowering them to make informed decisions quickly.”
rHEALTH’s innovative approach has already earned widespread recognition, including XPRIZE awards, NASA contracts, and a gravity-defying presentation aboard the International Space Station. Their Your Health, anywhere™ technology is set to redefine healthcare accessibility, bringing lab-quality diagnostics to the point of care.
For more information about rHEALTH and its groundbreaking work, visit www.rhealth.com.
Media Contact
Eugene Chan, rHEALTH, 1 617-913-7630, [email protected]
Revolutionizing Blood Testing: How rHEALTH’s New Coagulation Tests Are Transforming Patient Care
Table of Contents
- 1. Revolutionizing Blood Testing: How rHEALTH’s New Coagulation Tests Are Transforming Patient Care
- 2. Faster, More Accurate Diagnoses
- 3. NIH Funding Accelerates progress
- 4. Seamless Integration with Local Healthcare Providers
- 5. What’s Next for rHEALTH?
- 6. How do rHEALTH’s coagulation tests differ from traditional diagnostic methods?
- 7. Faster, More Accurate Diagnoses
- 8. NIH Funding Accelerates Progress
- 9. Seamless Integration with Local Healthcare Providers
By Archyde News Editor
January 14, 2025
In the ever-evolving world of medical technology, rHEALTH is making waves with its groundbreaking blood coagulation tests.These innovative diagnostics promise to transform the way healthcare providers approach conditions like hemophilia and other blood clotting disorders. dr. Emily Carter, Chief Medical Officer at rHEALTH, sat down with us to discuss how this technology is set to redefine patient care.
Faster, More Accurate Diagnoses
Traditional methods for diagnosing blood clotting disorders often involve lengthy processes and repetitive testing, which can delay critical treatment.Dr. Carter explains, “Our new coagulation tests are designed to provide faster, more accurate results, enabling healthcare providers to make timely and precise decisions. This can significantly improve patient outcomes, especially for those with life-threatening conditions.”
The key to this advancement lies in the integration of cutting-edge biomarkers and advanced algorithms. Unlike conventional methods that can take hours or even days, rHEALTH’s tests deliver actionable insights within minutes. “This not only reduces waiting times for patients but also minimizes the risk of complications during diagnostic delays,” Dr. Carter adds.
NIH Funding Accelerates progress
rHEALTH’s groundbreaking work has garnered significant support, including a $5 million grant from the National Institutes of Health (NIH). Dr. Carter emphasizes the importance of this funding: “The NIH’s support is invaluable. It allows us to fast-track our research, scale our development efforts, and expedite FDA approval.”
With this financial boost, rHEALTH is expanding its partnerships with clinical laboratories, including those in Ashburn, VA, where comprehensive blood tests are already being conducted. “This collaboration ensures that our technology is accessible to patients across diverse healthcare settings,” Dr. Carter notes.
Seamless Integration with Local Healthcare Providers
One of the key goals for rHEALTH is to integrate its technology with local healthcare providers, such as Solv Health, which offers same-day blood testing services. Dr. Carter explains, “Integrating our technology with providers like Solv Health is a priority. Their existing infrastructure for same-day blood testing aligns perfectly with our mission to deliver rapid diagnostics.”
By partnering with such facilities, rHEALTH aims to ensure that its coagulation tests are seamlessly implemented, making them available to patients without disrupting their current healthcare workflows.
What’s Next for rHEALTH?
Looking ahead, Dr. Carter shares that the focus is now on clinical trials and FDA approval. “Our goal is to bring this technology to as many patients as possible, ensuring that it becomes a standard part of diagnostic care,” she says. With the support of the NIH and partnerships with leading healthcare providers, rHEALTH is well on its way to achieving this vision.
As the medical community eagerly awaits the widespread adoption of these innovative tests, one thing is clear: rHEALTH’s advancements are poised to make a profound impact on patient care, offering hope and improved outcomes for those with blood clotting disorders.
The Future of Healthcare: A Revolutionary Approach to Diagnosis and Management
In a world where healthcare advancements are rapidly transforming the way we manage our health, a new technology is on the horizon. This groundbreaking innovation promises not only to diagnose conditions faster but also to ensure better management of our overall well-being.
Dr. Carter, a leading figure in this development, shares a message for patients eagerly awaiting these advancements: “We’re working tirelessly to bring you a solution that not only diagnoses your condition faster but also ensures better management of your health. This technology is not just a test—it’s a step toward a future where healthcare is more precise, proactive, and patient-centered.”
The initiative is not only focused on the technology itself but also on training healthcare providers to utilize it effectively. Once approved, the plan is to roll out these tests nationwide, starting with high-demand areas like Ashburn, VA, and eventually expanding globally.
This technology represents a significant leap forward in the healthcare industry. It aims to create a more patient-centered approach,where precision and proactive care are at the forefront. Dr. Carter emphasizes the importance of this innovation: “this is not just a test. It’s a step toward a future where healthcare is more precise, proactive, and patient-centered.”
As we look forward to these advancements transforming the healthcare landscape,it’s clear that this technology has the potential to revolutionize how we diagnose and manage health conditions. The journey toward this future is an exciting one, and we are eagerly anticipating its impact on the community.
For more information on blood testing services near you, visit solv Health.
How do rHEALTH’s coagulation tests differ from traditional diagnostic methods?
Revolutionizing Blood Testing: How rHEALTH’s New Coagulation Tests Are Transforming Patient Care
by Archyde News Editor
January 14, 2025
In the ever-evolving world of medical technology, rHEALTH is making waves with its groundbreaking blood coagulation tests. These innovative diagnostics promise to transform the way healthcare providers approach conditions like hemophilia and other blood clotting disorders. Dr. emily Carter, Chief medical Officer at rHEALTH, sat down with us to discuss how this technology is set to redefine patient care.
Faster, More Accurate Diagnoses
Archyde News Editor: Dr. Carter, can you elaborate on how rHEALTH’s coagulation tests differ from traditional diagnostic methods?
Dr.Emily Carter: Traditional methods for diagnosing blood clotting disorders often involve lengthy processes and repetitive testing, which can delay critical treatment. Our new coagulation tests are designed to provide faster, more accurate results, enabling healthcare providers to make timely and precise decisions. This can significantly improve patient outcomes, especially for those with life-threatening conditions.
Archyde News Editor: What is the key to this advancement?
Dr. Emily Carter: The key lies in the integration of cutting-edge biomarkers and advanced algorithms. Unlike conventional methods that can take hours or even days, rHEALTH’s tests deliver actionable insights within minutes. This not only reduces waiting times for patients but also minimizes the risk of complications during diagnostic delays.
NIH Funding Accelerates Progress
Archyde News Editor: rHEALTH has recently received a ample grant from the NIH. How will this funding impact the development of your technology?
Dr. emily Carter: The NIH’s support is invaluable. It allows us to fast-track our research, scale our development efforts, and expedite FDA approval.With this financial boost, we are expanding our partnerships with clinical laboratories, including those in ashburn, VA, where thorough blood tests are already being conducted. This collaboration ensures that our technology is accessible to patients across diverse healthcare settings.
Seamless Integration with Local Healthcare Providers
Archyde News Editor: one of rHEALTH’s key goals is to integrate its technology with local healthcare providers like Solv Health. Can you explain the importance of this integration?
Dr. Emily Carter: Integrating our technology with providers like Solv Health is a priority. Their existing infrastructure for same-day blood testing aligns perfectly with our mission to deliver rapid diagnostics. by partnering with such facilities, we aim to ensure that our coagulation tests are seamlessly implemented, making them accessible to patients in various healthcare settings.
Archyde News Editor: Dr. Carter, what are the long-term goals for rHEALTH’s coagulation tests?
Dr. Emily Carter: Our long-term goal is to democratize access to critical diagnostic tools. traditionally, tests for hemophilia A and anti-Xa inhibitors are confined to central labs.With rHEALTH’s technology, these tests can now be performed by patients and caregivers, empowering them to make informed decisions quickly. This shift not only improves accessibility but also enhances the quality of care for patients with blood clotting disorders.
Conclusion:
As rHEALTH continues to innovate and integrate its groundbreaking coagulation tests with local healthcare providers, the future of patient care looks brighter, faster, and more accurate. The support from the NIH and strategic partnerships with providers like Solv Health are pivotal steps toward achieving this vision. Dr. Emily Carter and her team at rHEALTH are leading the charge in revolutionizing blood testing, ensuring that life-saving diagnostics are accessible to all.
For more information about rHEALTH and its groundbreaking work, visit www.rhealth.com.
Media Contact: Eugene Chan, rHEALTH, 1 617-913-7630, [email protected]
By Archyde News Editor, January 14, 2025
